Effect of tadalafil on anaerobic performance indices in healthy athletes

British Journal of Sports Medicine

Volumn 42, Issue 2, 2008, Pages 130-133

  Guidetti, L ^a   Emerenziani, G P ^a   Gallotta, M C ^a   Pigozzi, F ^a   Di Luigi, L ^a   Baldari, C ^a  

^a UNIVERSITY OF ROME FORO ITALICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; PLACEBO; TADALAFIL;

ADULT; ANAEROBIC CAPACITY; ARTICLE; ATHLETE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXERCISE RECOVERY; FATIGUE; HUMAN; LACTATE BLOOD LEVEL; MALE; NORMAL HUMAN; PARAMETER; PERFORMANCE MEASUREMENT SYSTEM; STATISTICAL SIGNIFICANCE;

ANAEROBIC THRESHOLD; ATHLETIC PERFORMANCE; CARBOLINES; DOUBLE-BLIND METHOD; EXERCISE; EXERCISE TEST; HUMANS; LACTIC ACID; MALE; PHOSPHODIESTERASE INHIBITORS;

EID: 39449089792     PISSN: 03063674     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjsm.2007.037630     Document Type: Article

References (30)

1. Arruda-Olson AM, Mahoney DW, Nehra A, et al. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomised crossover trial. JAMA 2002;287:719- 25.
2. DeBusk RF, Pepine CJ, Glasser DB, et al. Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am J Cardiol 2004;93:147-53.
3. Ghofrani HA, Reichenberger F, Kohstall MG, et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med 2004;141:169-77.
4. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil. Am J Cardiol 2003;92:37-46M.
5. Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003;92:47-57M.
6. Hsu AR, Barnholt KE, Grundmann NK, et al. Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. J Appl Physiol 2006;100:2031-40.
7. Ricart A, Maristany J, Fort N, et al. Effects of sildenafil on the human response to acute hypoxia and exercise. High Alt Med Biol 2005;6:43-9.
8. Bocchi EA, Guimaraes G, Mocelin A, et al. Sildenafil effects on exercise, neurohormonal activation and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002;106:1097-103.
9. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol 2004;44:1488- 96.
10. Katz SD, Khan T, Zeballos GA, et al. Decreased activity of the L-arginine-nitric oxide metabolic pathway in patients with congestive heart failure. Circulation 1999;99:2113-17.
11. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-9.
12. Traverse JH, Chen YJ, Du R, et al. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. Circulation 2000;102:2997-3002.
13. Ahn HS, Foster M, Cable M, et al. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and non-vascular tissues. Adv Exp Med Biol 1991;308:191-7.
14. McCullough AR. An update on the PDE-5 inhibitors (PDE-5i). J Androl 2003;24:S52-8.
15. Loughney K, Taylor J, Florio VA. 3,5-Cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res 2005;17:320-5.
16. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.
17. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13:192-9.
18. Corbin JD, Francis SH. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Pract 2002;56:453-9.
19. Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J Am Pharm Assoc 2005;45:63-72.
20. max, aerobic, and anaerobic thresholds in normoxia. Int J Sports Med 2007; epub ahead of print.
21. Metra M, Raddino B, Dei Cas L, et al. Assessment of peak oxygen consumption, lactate and ventilatory thresholds and correlation with resting and exercise hemodynamic data in chronic congestive heart failure. Am J Cardiol 1990;65:1127-33.
22. 2max criteria: discontinuous versus continuous protocols. Med Sci Sports Exerc 1997;29:273-8.
23. Beneke R, Pollmann C, Bleif I, et al. How anaerobic is the Wingate Anaerobic Test for humans? Eur J Appl Physiol 2002;87:388-92.
24. Bishop D. Evaluation of the Accusport lactate analyzer. Int J Sports Med 2001;22:525-30.
25. Bishop D. Warm up II. Performance changes following active warm up and how to structure the warm up. Sports Med 2003;33:483-98.
26. Inbar O, Bar-Or O, Skinner JS. The Wingate Anaerobic Test. Champaign, IL: Human Kinetics, 1996.
27. McArdle WD, Katch FI and Katch VL. Exercise physiology. Baltimore, MD: Williams & Williams, 1996:101-19.
28. Hassan MA, Ketat AF. Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 2005;6:5-10.
29. Jackson G. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. Am J Cardiol 2005;96:32-6M.
30. Abdollahi M, Chan TS, Subrahmanyam V, et al. Effects of phosphodiesterase 3,4,5 inhibitors on hepatocyte cAMP levels, glycogenosis, gluconeogenesis and susceptibility to a mitochondrial toxin. Mol Cell Biochem 2003;252:205-11.